This work delineates a STIM1-STING circuit that maintains the resting state of the STING pathway.
T he ER provides a structural platform for activation of the type I interferon (IFN) response. STING, a key signaling adaptor protein for DNA-sensing pathways, localizes to the ER membrane in the resting state [1] [2] [3] . After activation by cytosolic DNAs, it translocates into the ER-Golgi intermediate compartment (ERGIC) to recruit TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). IRF3, on phosphorylation by TBK1, homodimerizes and translocates into the nucleus to induce transcription of type I IFNs [4] [5] [6] [7] . Beside an essential role in protecting the host against DNA pathogens, STING is also involved in the patho genesis of autoinflammation caused by self-DNAs in murine models 8, 9 . Accordingly, STING has been implicated in the pathogenesis of Aicardi-Goutieres syndrome, systemic lupus erythematosus, and other type I interferonopathies 10 . Furthermore, mutations in STING have been uncovered in patients with STING-associated vasculopathy with onset in infancy (SAVI) and lupus-like symptoms [11] [12] [13] . The STING variants found in SAVI patients are constitutively active and localize to the ERGIC without the STING ligand, cyclic dinucleotides (CDNs), suggesting that they may escape a mechanism that potentially maintains the ER localization of STING 14 . Given that CDNs can be generated by cytosolic self-DNAs derived from mitochondrial damage or genomic instability, and the binding affinity of STING for CDNs is high (∼ 5 nM for 2′ ,3′ cyclic guanosine monophosphate-adenosine monophosphate (2′ ,3′ -cGAMP)) 15 , active inhibitory mechanisms are necessary to tightly control its activation. However, little is known about how the resting state of STING is maintained.
High Ca 2+ concentration in the ER ([Ca 2+ ] ER ) is essential for its normal function. At the same time, diverse receptors elevate cytoplasmic [Ca 2+ ] by depleting ER Ca 2+ stores through a mechanism called store-operated Ca 2+ entry (SOCE). STIM1, an EF-handcontaining Ca 2+ -binding protein, localizes throughout the ER when [Ca 2+ ] ER is high, but, after depletion of the ER Ca 2+ stores, it translocates into junctional areas between the ER and plasma membrane, interacts with the pore subunit of store-operated Ca 2+ channels, Orai1, and induces Ca 2+ entry 16 . The essential role of STIM1 in effector function of adaptive immune cells, including T and B cells, has been well established [17] [18] [19] . Mutations in STIM1 cause severe combined immune deficiency (SCID) in humans 20 . Paradoxically, these patients also suffer from lymphoproliferative and autoimmune complications. Although for some forms of SCID the mechanisms behind these complications have been worked The Ca 2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum out-for example, poor development of both central and peripheral tolerance 21 -the underlying causes of inflammatory complications in patients harboring mutations in STIM1 are not known.
The role of STIM1 in cells of the innate immune system is currently unclear. Here, we examined the phenotypes of STIM1deficient cells and observed that loss of STIM1 induced spontaneous activation of the STING-TBK1-IRF3 pathway to activate type I IFN responses under sterile conditions in both murine and human cells. Mechanistically, STIM1 directly interacted with STING to retain it in an inactive state on the ER membrane. Accordingly, we also observed strong resistance to viral infections in STIM1 knockout cells and animals. These results suggest that STIM1 has an important role in regulation of the innate immune responses in addition to its well-established function in regulation of SOCE in adaptive immunity.
Results

STIM1 deficiency induces type I IFN response.
To gain insights into possible roles of STIM1 in innate immune responses, we checked expression of various inflammatory cytokines in Stim1 -/murine embryonic fibroblasts (MEFs). Among these, transcripts of Ifnb1 and Il6, as well as interferon-stimulated genes (ISGs) were significantly increased in Stim1 -/-MEFs compared with those in wild-type (WT) cells ( Fig. 1a) . Accordingly, we observed increased amounts of secreted IFN-β protein in culture supernatants from Stim1 -/-MEFs ( Fig. 1b) . Because of the well-established role of STIM1 in SOCE, it was possible that the increased type I IFN response in Stim1 -/-MEFs was a result of altered intracellular Ca 2+ homeostasis. To check this possibility, we compared responses between Stim1 -/and Orai1 -/-MEFs, both of which showed loss of SOCE ( Fig. 1c ). However, we did not observe enhanced Ifnb1 expression in Orai1 -/-MEFs, indicating that block of SOCE or altered intracellular Ca 2+ levels do not contribute to the increased type I IFN response observed in Stim1 -/-MEFs.
To verify these observations in primary cells, we examined bone-marrow-derived macrophages (BMDMs) from WT (Stim1 fl/fl ) and Stim1 fl/fl UBC-ERT2-cre mice to induce acute loss of STIM1 expression after tamoxifen treatment (Fig. 1d ). Similar to MEFs, we observed enhanced expression of Ifnb1 and Il6 transcripts in Stim1 -/-BMDMs. Next, we examined whether this enhanced type I IFN expression phenotype was conserved in human macrophages. We generated STIM1 -/-THP1 cells by clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR-Cas9)-mediated genome editing using two different guide RNA sequences ( Supplementary Fig. 1 ). Similar to murine cells, we observed an induction of IFNB1 and IL6 messenger RNAs and increased IFN-β secretion in STIM1 -/-THP1 clones (Fig. 1e,f) . Moreover, exogenous expression of STIM1 in these THP1 clones significantly rescued the phenotype by decreasing type I IFN expression. Taken together, these data strongly demonstrate an inhibitory role of STIM1 in type I IFN responses. STIM2 is another member of the STIM family that shares 66% amino acid sequence similarity with STIM1 16 . Both of them are ER-resident proteins, but they function differently in sensing depletion of the ER Ca 2+ stores and efficacy to activate Orai channels. STIM1 has a dominant role in activation of SOCE, whereas STIM2 is involved in ER Ca 2+ homeostasis by sensing subtle changes in [Ca 2+ ] ER 22, 23 . To check a possible function of STIM2 in regulation of type I IFN responses, we generated two independent STIM2 -/-THP1 clones. However, neither of the STIM2 knockout clones showed elevated expression of IFNB1 transcripts ( Supplementary Fig. 2 ). Collectively, these results establish a specific role for STIM1 in regulating the resting state of the type I IFN responses in murine and human cells.
STING-TBK1-IRF3 pathway links perturbation in STIM1
expression to IFN-β expression. Given that both STIM1 and STING, an important regulator for the type I IFN responses, localize to the ER membrane, we checked the possibility that STIM1 regulates the function of STING. On activation of STING via exposure to its ligand 2′ ,3′ -cGAMP, we observed a pronounced enhancement of Ifnb1 transcript and protein levels in Stim1 -/-, but not Orai1 -/-, MEFs when compared with those in WT MEFs ( Fig. 2a ). This higher type I IFN response in Stim1 -/-MEFs was also observed in the presence of cytosolic DNAs after transfection with IFN stimulatory DNA (ISD) or poly(dA:dT) that are known to activate the STING pathway, but not with poly(I:C), a poor agonist of the STING pathway ( Fig. 2b, left) . Similarly, we observed elevated transcripts of IFNB1 in STIM1 -/-THP1 cells transfected with 2′ ,3′ -cGAMP, but not poly(I:C) ( Fig. 2b, right) .
To determine whether deficiency of STIM1 induces an increase in type I IFN response through the STING-TBK1-IRF3 pathway, we checked for activated IRF3 and TBK1 in WT and Stim1 -/-MEFs. We examined localization of green fluorescent protein (GFP)-IRF3, which was exclusively in the cytoplasm in WT MEFs, but showed almost equal distribution in the cytoplasm and nuclei in Stim1 -/-MEFs ( Fig. 2c ). Biochemically, we detected enhanced homo-dimers of IRF3 in Stim1 -/-MEFs compared with WT cells under resting conditions ( Fig. 2d ). Furthermore, we found enhanced levels of phosphorylated TBK1 and accordingly increased the ratio of p-TBK1 versus total TBK1 in Stim1 -/-MEFs, BMDMs, and STIM1 -/-THP1 cells ( Fig. 2e ). We could also detect enhanced dimerization of endogenous STING in Stim1 -/-MEFs, which is considered an active form of STING ( Supplementary Fig. 3a ). Likewise, STIM1 -/-HEK293T cells stably expressing STING also showed enhanced STING dimers and multimers ( Supplementary Fig. 3b ). Next, we examined whether codeletion of STING in STIM1-deficient cells could rescue this enhanced IFN-β expression phenotype. Deletion of both Stim1 and Tmem173 (gene encoding STING) in MEFs (double knockout, DKO) markedly reduced Ifnb1 and Il6 transcripts under resting or cGAMP-treated conditions (Fig. 2f ). Co-deletion of Tmem173 also rescued increased IFN-β secretion observed in Stim1 -/-MEFs treated with poly(dA:dT) ( Fig. 2g ). We observed very similar results using THP1 cells. Deletion of both STIM1 and TMEM173 in DKO THP1 cells was confirmed by immunoblotting and SOCE measurements ( Fig. 2h ). DKO THP1 cells showed reduced IFNB1 and IL6 mRNA levels, suggesting that the elevated cytokine expression in STIM1 -/-THP1 cells were derived from increased STING activity. Together, these results suggest that the increase in type I IFN responses observed in STIM1-deficient cells is mediated by the STING-TBK1-IRF3 pathway, and STIM1 has an important role in type I IFN signaling via regulating STING function.
Increased type I IFN responses in patient lacking STIM1 expression.
Previously, patients showing SCID symptoms and bearing homozygous nonsense mutation of STIM1 (E136X) were shown to lack STIM1 expression due to nonsense-mediated mRNA decay 24 . To mimic the phenotype of this patient, we transduced STIM1deficient cells with viral vectors encoding WT and STIM1 E136X proteins. We confirmed lack of STIM1 expression in Stim1 -/-MEFs transduced to express STIM1 E136X , whereas those with STIM1 WT showed expression similar to the endogenous protein in WT MEFs (Fig. 3a) . Notably, expression of STIM1 WT , but not STIM1 E136X , rescued the increased type I IFN response in Stim1 -/-MEFs (Fig. 3b ).
To examine whether this was true in STIM1-deficient patients, we collected primary cells from a patient lacking STIM1 expression as a result of a homozygous STIM1 mutation, c.478del, p.(Ser160fs). The lack of STIM1 expression in the patient's peripheral blood mononuclear cells (PBMCs) was confirmed by immunoblotting ( Fig. 3c ). Patient serum showed enhanced IFN-β , interleukin-6 (IL-6), and tumor-necrosis factor (TNF) cytokines when compared with those observed in three healthy controls ( Fig. 3d ). Consistently, we also observed enhanced expression of ISGs in PBMCs and monocytes from the patient, when compared with those in two healthy controls ( Fig. 3e) . Notably, the patient also exhibited very mild SAVI-like symptoms-he suffered from desquamation and blistering with skin eruptions mainly affecting the palm, soles of the feet, and cheeks. He also showed pronounced nail dystrophy 25 . Together, these data confirm that loss of STIM1 in humans enhances expression of type I IFN, pro-inflammatory cytokines, and ISGs, similar to murine cells. STIM1 interacts with STING for its retention at the ER. The increased type I IFN response, together with higher basal activity of the STING-TBK1-IRF3 pathway, in STIM1-deficient cells suggests that STIM1 may be involved in maintaining the resting state of the STING pathway. Microscopy analysis showed a strong colocalization between STIM1 and STING in the ER (Fig. 4a ). Hence, we checked whether STIM1 can physically interact with STING to retain it in the ER. When coexpressed in HEK293T cells, STIM1 was specifically identified from immunoprecipitates of STING ( Fig. 4b ). In addition, we also validated association between endogenous STIM1 and STING proteins by immunoprecipitation ( Fig. 4c ). This association was specific because another ER-resident protein, calnexin, could not be detected in immunoprecipitates of STIM1.
Next, we examined the association between STIM1 and STING on activation of either of the proteins. We activated STIM1 by treatment with thapsigargin that depletes the ER Ca 2+ stores, and activated STING using its ligand, 2′ ,3′ -cGAMP. We observed reduced biochemical association between the two proteins by stimulation of either STIM1 or STING (Fig. 4d ). These data indicate that STING and STIM1 form a protein complex that is dissociated as a result of conformational changes induced by stimulation of either of these proteins. Association between STING and STIM1 prompted us to check for a possible role of STING in regulating the function of STIM1. We observed reduced SOCE induced by thapsigargin or anti-CD3 antibody treatment in HEK293T and Jurkat T cells overexpressing STING ( Supplementary Fig. 4a ,b,c). In addition, we observed enhanced STIM1 translocation to the ER-plasmamembrane (PM) junctions in thapsigargin-treated STING-deficient (Tmem173 -/-) MEFs ( Supplementary Fig. 4d ). Conversely, there was significant enhancement of SOCE in TMEM173 -/-Jurkat cells ( Supplementary Fig. 4e ,f). This enhancement was not observed in THP1 cells, indicating cell-type specificity (Fig. 2h ). Taken together, these data show that association with STING impacts the function of STIM1 in mediating SOCE. STING contains four transmembrane segments in its N terminus that span the ER membrane ( Fig. 4e) 1 . STING N-terminal domain (NTD) containing the transmembrane segments has an important role in its ER localization, trafficking, and interaction with regulators including ZDHHC1, AMFR, TRIM32, and RNF5 [26] [27] [28] [29] . Tumor DNA viral proteins, E1A and E7, also bind to STING NTD to Stim1 inhibit downstream signaling 28 . The cytoplasmic region (C-terminal domain, CTD) of STING contains the dimerization domain, CDNbinding region, and the C-terminal tail that interacts with TBK1 and IRF3. STIM1 has an N-terminal ER-luminal region containing the Ca 2+ -sensing EF-hand motifs and sterile alpha motif domain that is important for its multimerization after ER Ca 2+ depletion. It also has a single transmembrane domain that traverses the ER membrane. The cytoplasmic C terminus contains multiple functional domains, including coiled-coil domain (CC) 1, CC2, CC3, a serine/threonine-rich (S/T) domain, and a lysine-rich domain (poly-K), that are important for binding to the plasma membrane after depletion of ER Ca 2+ stores. A fragment containing CC2 and CC3 of STIM1 called the CRAC activation domain or the STIM1 Orai activating region was identified to interact directly with Orai1 subunits to gate them 16, 29 .
To determine their interaction domains, we carried out coimmunoprecipitation using lysates of HEK293T cells overexpressing full-length, NTD, or CTD of STING together with full-length STIM1. These results showed NTD of STING as a major STIM1interacting domain, whereas its CTD interacted weakly with STIM1 ( Fig. 4f , left panels). To uncover the domain(s) of STIM1 involved in interaction with STING, we performed glutathione S-transferase (GST) pull-down experiments by incubating bacterially purified GST-fused fragments of STIM1 with lysates of HEK293T cells overexpressing full-length, NTD, or CTD of STING. From this analysis, we identified a predominant interaction between the N terminus of STIM1 containing the transmembrane segment (amino acids 1-249) and STING NTD, and a weaker binding of the cytoplasmic fragment predominantly containing the serine/threonine-rich domain of STIM1 to STING CTD (Fig. 4f, right panels) . These data suggest that interaction between STIM1 and STING is predominantly mediated by their transmembrane domains on the ER membrane, with weak additional interactions between their cytoplasmic regions. STIM1 acts as an ER retention factor to suppress the activity of STING. Ligand binding induces conformational rearrangement and trafficking of STING from the ER to the ERGIC and the Golgi apparatus 14, 30, 31 . Given that STIM1 interacted strongly with STING NTD, which is crucial for STING localization, we hypothesized that STIM1 may control the ER localization of STING. To validate this hypothesis, we examined the localization of STING in WT and Stim1 -/-MEFs by co-staining with ERGIC marker (ERGIC-53/p58). We observed a significant population of Stim1 -/-MEFs showing partial localization of STING at the ERGIC without any stimulation, and this population increased much faster in Stim1 -/-MEFs infected with the DNA virus, herpes simplex virus type-1 (HSV-1), when compared with WT MEFs (Fig. 5a ). To check how interaction with STIM1 influences the function of STING, we monitored the translocation kinetics of STING after treatment of WT or Stim1 -/-MEFs with 2′ ,3′ -cGAMP and observed faster translocation of STING into the ERGIC in Stim1 -/-MEFs than in WT cells ( Fig. 5b ). Together with our biochemical analysis, these data suggest that STIM1 physically interacts with STING to promote its retention onto the ER membrane. We checked whether overexpression of STIM1 can inhibit the function of STING using Ifnb-promoter-driven luciferase reporter (IFN-Luc) assays after 2′ ,3′ -cGAMP treatment. In cells coexpressing STING and increasing amounts of full-length or the N-and C-terminal binding fragments of STIM1, we observed a dosedependent inhibition of luciferase reporter expression ( Fig. 5c ).
In support of our biochemical analyses, the N-terminal transmembrane-containing fragment of STIM1 (amino acids 1-249) showed a stronger inhibition of luciferase reporter activity than the cytoplasmic domain (amino acids 400-600), whereas STIM1 fragments (amino acids 250-400 and 600-685) that do not interact with STING did not affect luciferase activity. Of note, expression of full-length STIM1 or its N-terminal fragment (amino acids 1-249) did not influence the luciferase activity when stimulated with poly(I:C). These data validate functional interaction between STIM1 and STING proteins. The genetic lesions of patients exhibiting autoinflammatory vasculopathy and autoimmunity were mapped to single amino acid substitutions in STING 11 . These substitution mutations changed one of the conserved residues, V147, N154, or V155, all of which are localized in or around the STING dimerization domain 32 . In addition, these substitutions lead to localization of STING at the ERGIC and constitutive TBK1 and IRF3 activation and uncontrolled type I IFN response 11, 13 . We examined whether these disease-associated STING mutants retained binding to STIM1. Using immunoprecipitation analysis, we observed reduced interaction of the STING SAVI mutants with STIM1, and overexpression of full-length or the N-terminal fragment of STIM1 could suppress Ifnb-promoterdriven luciferase activity of these mutants ( Supplementary Fig. 5a,b) . In support of these data, confocal analyses showed a partial block of constitutive ERGIC localization of these mutants in the presence of STIM1 ( Supplementary Fig. 5c ). Collectively, these results confirm the previous observations that exit from the ER is an important step for the activation of STING and that STIM1 can block this trafficking via direct interaction.
Genetic inhibition of STIM1 expression primes antiviral activity.
We sought to determine whether deficiency of STIM1 influences activation of the type I IFNs in response to DNA virus infection. To examine this, WT and Stim1 -/-MEFs were infected with DNA viruses (for example, HSV-1 and murine γ -herpesvirus, MHV-68). Spontaneous induction of IFN-β observed in Stim1 -/-MEFs was substantially increased after HSV-1 infection (Fig. 6a) . We also observed a marked reduction in expression of GFP, encoded from the viral genome, which served as an indicator for viral replication in Stim1 -/-MEFs. We observed similar results using another DNA virus, MHV-68. Similar to HSV-1 infection, MHV-68-infected Stim1 -/-MEFs showed much lower expression of the viral-genomedriven GFP, as well as early and late phase viral transcripts (for example, ORF57 and ORF29, respectively), indicative of a lower viral burden (Fig. 6b ). Consistent with these data, Stim1 -/-MEFs showed enhanced phosphorylation of IRF3 on HSV-1 infection (Fig. 6c ). We observed similar results in primary cells, where Stim1 -/-BMDMs showed enhanced expression of Ifnb1 and Il6 mRNAs under resting conditions, as well as after HSV-1 infection (Fig. 6d ). Together, these data show that the loss of STIM1 increases resistance to DNA virus infections.
Next, we validated these observations in STIM1 -/-THP1 macrophages. Similar to data with mouse cells, STIM1 deficiency rendered human macrophages resistant to HSV-1, decreasing expression of GFP as observed by microscopy and transcript analyses (Fig. 6e) . Accordingly, we observed enhanced expression of IFNB1 transcripts in STIM1 -/-THP1 cells. Previously, it was shown that anti viral immunity against HIV infection also relies on the cGAS-STING pathway as a result of the presence of cytosolic DNA generated by reverse transcription 8, 33 . To investigate whether STIM1 deletion imparts resistance to HIV, we infected WT and STIM1 -/-THP1 cells with GFP-HIV and observed a dramatic reduction of HIV infection in STIM1 -/-THP1 cells as judged by frequency of GFP + cells (Fig. 6f ). Together, these results suggest that deficiency of STIM1 can prime host response against infection with DNA viruses and retroviruses in various murine and human cell types.
Many DNA viruses, including HSV-1, are known to activate Ca 2+ signaling for a productive infection 34 . Hence, it is possible that resistance to DNA virus infection in Stim1 -/-MEFs may be due to loss of SOCE. To determine the contribution of SOCE versus enhanced STING activity in host resistance to DNA virus infection, we compared responses of Stim1 -/and Orai1 -/-MEFs to HSV-1 infection. We observed a moderate resistance to HSV-1 infection in Orai1 -/-MEFs, but, in comparison, the resistance to HSV-1 infection was approximately 100-fold more pronounced in Stim1 -/cells ( Supplementary Fig. 6a ). In support of the SOCE-independent role of STIM1 in regulation of STING function, we found that Ifnb1 mRNA expression was not increased after HSV-1 infection in Orai1 -/cells, contrary to Stim1 -/cells. Finally, Stim1 -/-MEFs, when treated with an inhibitor of the IFN-receptor-JAK-STAT pathway, tofacitinib, became susceptible to HSV-1 infection ( Supplementary  Fig. 6b ). Together, these results indicate a predominant role of the type I IFN pathway in the resistance of STIM1-deficient cells to DNA virus infections.
Ablation of STIM1 primes type I IFN response in vivo.
To gain insight into the importance of STIM1 in host defense against viral infection in vivo, we investigated the antiviral immune response in Stim1 fl/fl and Stim1 fl/fl Lyz2-cre mice. In parallel, to compare the contribution of SOCE in host resistance to viral infections, we generated conditionally targeted Orai1 animals ( Supplementary Fig. 7a ), which were bred with Lyz2-cre for two generations. BMDMs differentiated from bone marrows of Orai1 fl/fl Lyz2-cre animals showed almost a complete loss of Orai1 transcripts and SOCE ( Supplementary Fig. 7b,c) . Given that HSV-1 is a neurotropic virus and the leading cause of sporadic viral encephalitis, we investigated the effects of Orai1 and Stim1 deficiency on HSV-1-induced lethality and viral loads in the brain. When infected with HSV-1 intravenously, control (Stim1 fl/fl and Orai1 fl/fl ) as well as Orai1 fl/fl Lyz2-cre animals showed susceptibility and died within 6-8 d of infection ( Fig. 7a,b) . In contrast, Stim1 fl/fl Lyz2-cre mice were completely resistant to HSV-1-induced lethality and, accordingly, recovered from loss of body weight. Viral titers in the brains obtained from Stim1 fl/fl Lyz2-cre mice were significantly lower than Stim1 fl/fl animals (Fig. 7c) . Notably, serum cytokine measurements showed elevated levels of serum IFN-β , IL-6, and TNF in uninfected as well as HSV-1-infected Stim1 fl/fl Lyz2-cre mice, when compared with littermate controls (Fig. 7d ). Taken together, our data indicate that genetic deletion of Stim1, but not Orai1, can impart protection from HSVinduced encephalitis and lethality, as a result of pre-activation of the STING-mediated type I IFN signaling pathway.
Discussion
STING and STIM1 commonly contain transmembrane domain(s) in their N termini and predominantly localize to the ER membrane. Co-immunoprecipitation experiments showed an association between the two proteins, which was primarily mediated by their N-terminal transmembrane domains. We showed that loss of STIM1 renders cells and mice strongly resistant to viral infections resulting from enhanced expression of type I IFNs and proinflammatory cytokines. Notably, a patient with a mutation in STIM1 that abrogated STIM1 expression also showed elevated cytokines and ISGs. Furthermore, some of the patient's clinical features, principally the skin and nail manifestations, resemble those of SAVI patients, suggesting that the excessive type I IFNs do have adverse biological manifestations in this condition 25 . Mechanistically, enhanced translocation and dimerization of STING by STIM1 deficiency suggest that STIM1 may preferentially bind to STING monomers at the ER to prevent its spontaneous activation. Conversely, we also found that STING deficiency augmented translocation of STIM1 and Ca 2+ entry triggered by depletion of ER Ca 2+ stores. Thus, our studies suggest that physical and functional association between STIM1 and STING are crucial for maintenance of the resting state of both pathways. We found that enhanced type I IFN expression in STIM1deficient cells is not mediated by Ca 2+ signaling by comparative studies with Orai1-deficient cells and animals. STIM1 deficiency made cells and mice strongly resistant to HSV-1 infections. Given that many viruses, including HSV-1 34 , require elevated Ca 2+ levels for their replication, we determined the contribution of the Ca 2+dependent (that is, decreased SOCE) versus Ca 2+ -independent mechanisms (that is, enhanced type I IFN response) involved in antiviral immunity in STIM1-deficient cells using two independent molecular tools, Orai1 -/cells and mice and JAK inhibitors. These results suggest that decreased viral burden in STIM1-deficient cells and mice is predominantly derived from enhanced type I IFN responses. Whether the same principle can be applied to other viruses with various degrees of dependence on Ca 2+ signaling and activation of the STING pathway needs further study.
Although much is understood regarding the mechanisms underlying activation of STING, including ligand binding, trafficking, and interaction with downstream effector molecules, little is known about regulation of its resting state. Multiple mechanisms underlying STING inhibition have been uncovered as a result of the importance of timely inactivation of the type I IFN signaling pathway. NLRX1 and ATG9a have been shown to inhibit STING-TBK1 interaction 26, 27 . In addition, K48-linked polyubiquitination by RNF5 and TRIM30a results in STING degradation after ligand binding 35, 36 . All of these inhibitory mechanisms target STING function after ligand binding and trafficking. However, inhibition of STING trafficking by brefeldin A, an inhibitor of ADP ribosylation factor (ARF) GTPases, blocks activation of the downstream pathway, suggesting that trafficking of STING is crucial for its function 14 . Consistently, our studies revealed a mechanism of regulation of STING activity, inhibition of STING trafficking via direct interaction with STIM1. Activity of three of the disease-associated STING variants, V147L, N154S, and V155M, was suppressed by STIM1 in part via blocking their translocation to the ERGIC, demonstrating a therapeutic potential of our finding. In summary, our study identifies STIM1 as an 'ER retention factor' to maintain ER residency and inactive conformation of STING. Furthermore, we found that one of the primary functions of CDN binding to STING is to disrupt its association with STIM1 that would allow exit of STING from the ER. Further dissection of the mechanisms underlying maintenance of the resting state of STING may inform the design of specific therapeutic strategies geared towards enhancement/inhibition of STING activity in the context of vaccination and sterile inflammatory diseases (for example, Aicardi-Goutieres syndrome and SAVI), respectively.
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Methods
Chemicals and antibodies. Fura 2-AM (F1221) was purchased from ThermoFisher. Thapsigargin and ionomycin were purchased from EMD Millipore. Poly(I:C) (P1530) was purchased from Millipore Sigma. Poly(dA:dT) (tlrl-patn) and 2′ ,3′ -cGAMP (tlrl-nacga23) were purchased from InvivoGen. Tofacitinib (S500110MG) was purchased from Selleck Chemical LLC. Antibodies for detection of STIM1 (5668S), phosphor-IRF3 (29047S), IRF3 (4302S), phosphor-TBK1 (5483S), total TBK1 (3504S), STING (13647S), 6xHis tag (12698S), and STIM2 (4917S) were purchased from Cell Signaling Technologies. Antibodies for detection of FLAG tag (F3040), p58 (ERGIC marker, E1031), and human Orai1 (AB9868) were purchased from Millipore Sigma. Antibody for detection of β -actin (sc-47778) was obtained from Santa Cruz Biotechnology and antibodies for detection of STIM1 (clone 5A2) and GAPDH (GTX100118) from human PBMCs were obtained from Sigma and GeneTex, respectively.
Plasmids and cells. STIM1-YFP plasmid has been described previously 37 . Human STIM1 complementary DNA was subcloned into a lentiviral vector, FGllF (kind gift from D. Sun An, University of California, Los Angeles (UCLA)), with a C-terminal FLAG tag and pcDNA 3.1 mychis plasmid. GST-tagged truncated fragments of STIM1 corresponding to amino acids 1-249 (containing the EF-hand, sterile alpha motif domain, and transmembrane segment), 250-400 (containing CC1 and CC2), the CRAC activation domain (amino acids 342-448), 400-600 (the serine and threonine-rich region), and 600-685 (the C-terminal PIP 2 -interacting domain) have been previously described 37 . Fragments of STING corresponding to the N-terminal transmembrane domain (amino acids 1-154) and CTD (amino acids 149-379), both tagged with a FLAG tag in the C terminus, were subcloned into pMSCV-CITE-eGFP-PGK-Puro vector. Full-length cDNA of human STING and SAVI mutants corresponding to V147L, N154S, and V155M were subcloned into pEGFPN1 vector to generate a C-terminal GFP fusion protein and into pMSCV-CITE-eGFP-PGK-Puro vector that encodes a C-terminal FLAG tag using primers described in Supplementary Table 1 . Oligonucleotides encoding single guide RNAs (sgRNAs) to delete STIM1, STIM2, and STING were subcloned into lentiGuide-Puro vector (Addgene, #52963). HEK293T, Vero, and Jurkat E6-1 T cell lines were obtained from the American Type Culture Collection center. WT and Stim1 −/− MEFs were generated by breeding Stim1 fl/fl mice (Jackson Laboratory, stock no. 023350) with CMV-cre mice (Jackson Laboratory, stock no. 006054). MEFs were established using standard protocols from embryonic day 14.5 embryos and retrovirally transduced with SV40 large T antigen in a plasmid encoding hygromycin resistance for immortalization. Orai1 −/− MEFs have been previously described 38 .
Cell culture. MEFs, Vero, and HEK293T cells were grown in complete DMEM (Mediatech) supplemented with 10% (v/v) fetal bovine serum (Hyclone), 2 mM L-glutamine (Mediatech), 10 mM HEPES (Mediatech), and Penicillin/Streptomycin (Mediatech) at 37°C and 5% CO 2 . BMDMs were differentiated from bone marrow cells isolated from femur and tibia of 6-8-week-old mice. For preparation of BMDMs, the bone marrow cells were cultured in 10% macrophage-colonystimulating factor (M-CSF)-containing conditional medium from HEK293T cells expressing recombinant M-CSF (a kind gift from Stephen Smale's laboratory, UCLA) for 4-6 d. BMDMs were cultured in the absence of M-CSF for at least 24 h before experimental use. THP1 and Jurkat T cells were cultured in RPMI (Rosewell Park Memorial Institute medium, Mediatech) containing 10% fetal bovine serum (Hyclone). Cells were infected with indicated multiplicity of infection (MOIs) of indicated viruses and collected in TRIzol reagent for transcript expression analysis. For 2′ ,3′ -cGAMP treatment, MEFs or HEK293T cells were treated with or without 1 μ M 2′ ,3′ -cGAMP for 30 min in digitonin permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl 2 , 0.1 mM dithiothreitol, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, pH 7.0) followed by culture medium for indicated times, after which the cells were collected for transcript analysis or reporter assays. MEFs were transfected with 5 μ g ISD 39 , polyd(A:dT), or poly(I:C) using Lipofectamine 2000 (ThermoFisher). For enzyme-linked immunosorbent assays (ELISAs), MEFs were treated with cGAMP as described and supernatant collected after 24 h.
Mice. Stim1 fl/fl animals were purchased from Jackson Laboratory (stock no. 023350) and bred with Lyz2-cre animals (Jackson Laboratory, stock no. 004781) for two generations. Targeting of murine Orai1 was performed by flanking exon 2 with LoxP sites by homologous recombination in AB2.2 (129SvEv) embryonic stem cells. Exon 2 encodes for 201 amino acids of a total of 304 amino acids of Orai1 protein. G418-resistant clones were screened by PCR for homologous recombination at both homology arms. Chimeric mice with floxed Orai1 alleles were generated by blastocyst injection of heterozygous Orai1 fl/+ embryonic stem cell clones. Founder Orai1 fl/+ mice were bred with Flp-deleter mice (Jackson Laboratory) to remove the neomycin resistance gene cassette. Orai1 fl/fl mice were backcrossed to C57/BL6/J mice for at least ten generations and then bred with Lyz2-cre mice to generate myeloid-specific deletion of Orai1. All mice were maintained in pathogen-free barrier facilities and used in accordance with protocols approved by the Institutional Animal Care and Use Committee at the UCLA.
Patient. Sample collection from the patient was performed after obtaining written consent from his parents according to the principles of the Declaration of Helsinki and after local ethics approval. Detailed clinical evaluation was undertaken in appropriate clinical setting. PBMC isolation from healthy control and patient human blood samples was performed by gradient separation using Lymphoprep (Stem Cell Technologies). Monocytes were purified from PBMCs using a Monocytes separation kit II (no. 130-091-153, Miltenyi Biotec). The patient is a 4-year-old boy of consanguineous Pakistani background, who initially presented to pediatric neurology due to poor mobility. A diagnosis of STIM1 deficiency was made following referral to pediatric immunology due to recurrent sinopulmonary infections. The patient has typical non-immunological features consistent with STIM1 deficiency including amelogenesis imperfecta resulting in complete dental clearance, anhidrosis, and muscle weakness. Surprisingly, the patient had mild immunodeficiency phenotype, with relatively preserved immunological function, including appropriate responses to challenge vaccination 25 .
Virus amplification and concentration. MHV-68-GFP virus was amplified and titrated in NIH3T3 cells using standard protocols. HSV-1 KOS strain was used for all in vitro experiments and HSV-1 17 + strain was used for in vivo infection experiments. Both of the strains were amplified and titrated in Vero cells using standard protocols. HSV-1 17 + strain was concentrated for in vivo experiments. VSV-G pseudotyped HIV-1 NL4-3 strain-GFP reporter virus was amplified and titrated in HEK293T cells using standard protocols.
RNA isolation, cDNA synthesis, and real-time quantitative PCR (qPCR).
Total RNA from cells collected in TRIzol reagent (ThermoFisher) was isolated using the Direct-zol RNA isolation kit (Zymo Research). RNA quantity and quality were confirmed with a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized using 2-3 μ g of total RNA using oligo(dT) primers and Maxima Reverse Transcriptase (ThermoFisher). Real-time qPCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad) and an iCycler IQ5 system (Bio-Rad) using gene-specific primers described in Supplementary Table 1 . Threshold cycles (C T ) for all of the candidate genes were normalized to those for 36b4 to obtain Δ C T and further normalized to the values obtained for WT samples to obtain Δ Δ C T . The specificity of primers was examined by melt-curve analysis and agarose gel electrophoresis of PCR products. Total RNA from human patient and healthy donor PBMCs and monocytes collected was isolated using the Total RNA purification Kit (Norgen Biotek Corp.). cDNA was synthesized using 1-2 μ g total RNA using High-Capacity cDNA Reverse Transcription Kit (ThermoFisher). Real-time qPCR was performed using TaqMan Universal PCR Master Mix (ThermoFisher) using FAM-MGB probes for detection of MX1 (Hs00895608_m1), IFI44 (Hs00951349), IFI44L (Hs00915292_m1), IFI27 (Hs01086370_m1), ISG15 (Hs00192713_m1), CXCL10 (Hs01124251_g1), RSAD2 (Hs01057264_m1), IFIT1 (Hs01675197_m1), IFI6 (Hs00242571_m1), OAS1 (Hs00973635_m1), IL6 (Hs00985639_m1), and HPRT1 (Hs99999909_m1). The relative abundance of each transcript was normalized to the expression level of HPRT1 to obtain Δ C T and further normalized to the values obtained for healthy controls to obtain Δ Δ C T .
Cytokine measurement by ELISA. ELISA was performed on cell culture supernatants from indicated cells or serum samples collected from mock or HSV-1-infected animals for detection of IFN-β (Biolegend, no. 439407), IL-6 (ThermoFisher, no. 88-7064-88), and TNF (ThermoFisher, no. 88-7324-88). Serum samples obtained from healthy controls or the STIM1-deficient human patient were used for detection of IFN-β (PBL Assay Science, no. 41410), IL-6 (ThermoFisher, no. 88-7066-22), and TNF (ThermoFisher, no. 88-7346-22).
Single-cell Ca 2+ imaging, live-cell epifluorescence or total internal reflection fluorescence (TIRF) microscopy, and confocal microscopy. THP1 and Jurkat T cells were loaded at 1 × 10 6 cells per ml with 1 μ M Fura 2-AM for 40 min at 25 °C and attached to poly-L-lysine-coated coverslips. MEFs or BMDMs were grown overnight on coverslips and loaded with 1 μ M Fura 2-AM for 40 min at 25 °C for imaging. Intracellular [Ca 2+ ] i measurements were performed using essentially the same methods as previously described 40 . For live-cell epifluorescence imaging of STING-GFP translocation kinetics, MEFs grown on coverslips were perfused with Ringer's solution containing (in mM): 155 NaCl, 4.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 D-glucose, and 5 Na-HEPES (pH 7.4), and used for time course imaging. Cells were perfused with digitonin permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl 2 , 0.1 mM dithiothreitol, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, pH 7.0) containing 1 μ M 2′ ,3′ -cGAMP for 10 min and then the medium was replaced with Ringer's solution. For TIRF analysis of STIM1-YFP translocation, MEFs were plated onto coverslip bottom dishes in medium and used for experiments. Medium was replaced with Ringer's solution and cells were treated with 1 μ M thapsigargin for passive depletion of ER Ca 2+ stores to monitor STIM1 translocation. TIRF microscopy was performed using an Olympus IX2 illumination system mounted on an Olympus IX51 inverted microscope using previously described methods 37 . Acquisition and image analysis were performed using Slidebook (Intelligent Imaging Innovations) software and graphs were plotted using OriginPro8.5 (Originlab). For quantification of TIRF intensity across different cells, individual regions of interest were selected and data were analyzed 1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code Data collection SLidebook 6.0 for Ca2+ imaging data, iQ5 for qPCR data, Fluoview and NIS-Elements for confocal data, BMG plate-reader for ELISA data, ImageReader LAS3000 for chemiluminescence data, BDFortessa for flow cytometry Data analysis Origin Pro8.5 and Origin Pro 2018(b) for graphs and statistical tests, MultiGuage v3.1 for immunoblotting and densitometry analysis, Fluoview and NIS-Elements Viewer 4.2 for confocal data analysis and FlowJo 8.8.6 for FACS data For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding authors upon request.
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Sample size
For in vivo experiments the following power analysis was used to determine group size: an effect size of 30% difference in expression of cytokines is expected to show significance, and the variance within groups can be 15%. In order to have a power of 0.8 and a probability of type I error of 0.5 or less, we used at least 5 animals per group. 
Data exclusions
Antibodies Antibodies used
Antibodies for detection of STIM1 (5668S), phosphor-IRF3 (29047S), IRF3 (4302S), phosphor-TBK1 (5483S), total TBK1 (3504S), STING (13647S), 6xHis tag (12698S), and STIM2 (4917S) were purchased from Cell Signaling Technologies. Antibodies for detection of FLAG tag (F3040), p58 (ERGIC marker, E1031) and human Orai1 (AB9868) were purchased from Millipore Sigma. Antibody for detection of -actin (sc-47778) was obtained from Santa Cruz Biotechnology and antibodies for detection of STIM1 (clone 5A2) and GAPDH (GTX100118) from human PBMCs were obtained from Sigma and GeneTex respectively.
Validation
Many antibodies are already validated based on manufacturer's data (especially those from Cell Signaling Technologies) and their widespread use in various published articles. Some of the Abs we validated ourselves using KO cell lines as indicated in figure legends and methods section.
